We clearly analyze, identify and describe the physicochemical properties and development process of our VC linker-based CD47-targeted ADCs, although anti-CD47-DM1 based on Sulfo-SMCC linker for treating triple-negative breast cancers was reported by Si, et al., in August 2021 (36). Here, CD47 is linked to triple-negative breast carcinoma.